WMSA
IMDX

Weiss Multi-Strategy Advisers’s Insight Molecular Diagnostics IMDX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,250
Closed -$99K – 603
2019
Q1 		$99K Buy
+1,250
New +$80.6K ﹤0.01% 489

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Weiss Multi-Strategy Advisers's IMDX Position: Q2 2019 in Review

Weiss Multi-Strategy Advisers sold out of Insight Molecular Diagnostics (IMDX) in Q2 2019, closing a stake of 1,250 shares — an estimated $99K sold.

Weiss Multi-Strategy Advisers first reported a position in IMDX in Q1 2019 and held it in 1 quarter. The position peaked at $99K in Q1 2019. 54 funds tracked by Wall St. Rank hold IMDX as of Q2 2019.

  • Weiss Multi-Strategy Advisers reported no remaining Insight Molecular Diagnostics position as of Q2 2019 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 1,250 Insight Molecular Diagnostics shares in Q2 2019, an estimated $99K.
  • Weiss Multi-Strategy Advisers first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 1 quarter.
  • Weiss Multi-Strategy Advisers's Insight Molecular Diagnostics position peaked at $99K in Q1 2019.
  • 54 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2019.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.